TAIWAN BIOTECH CO., LTD.
|TAIWAN BIOTECH CO., LTD. Patent applications|
|Patent application number||Title||Published|
|20130078304||CONTROLLED RELEASE FORMULATION FOR TREATING SLEEP DISORDERS - The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form and Zolpidem or a pharmaceutically acceptable salt thereof in sustained release form, wherein Zaleplon or a pharmaceutically acceptable salt thereof and Zolpidem or a pharmaceutically acceptable salt thereof are released in two phases where the first phase is a immediate release phase of Zaleplon or a pharmaceutically acceptable salt thereof and the second phase is a sustained release phase of Zolpidem or a pharmaceutically acceptable salt thereof.||03-28-2013|
|20130035490||Method For Making Donepezil - The method in accordance with the present invention has: mixing E2M, an organic solvent, a weak base, sodium dithionite, and a phase transfer catalyst to obtain an E2M mixture solution; heating the E2M mixture solution and adding water to obtain a heated E2M aqueous solution having an organic layer; and extracting the organic layer from the heated E2M aqueous solution, and condensing and drying the organic layer to obtain donepezil. Employing sodium dithionite as a reducing agent improves safety over hydrogen gas used in conventional methods and lowers the cost in contrast to the conventional noble metal catalysts that are extremely expensive. Furthermore, the method of the present invention requires only 60 minutes of reaction time to synthesize donepezil with a promising yield more than 85%, which greatly raises the efficiency and economic value of the manufacture of donepezil.||02-07-2013|
|20120027853||PROCESS FOR PREPARATION OF ANTI-TUBERCULAR COMBINATION AND PHARMACEUTICAL COMPOSITION PREPARED THEREFROM - This invention relates to a process for preparing a pharmaceutical composition comprising four antitubercular drugs: rifampin or a pharmaceutically acceptable salt thereof, isoniazid or a pharmaceutically acceptable salt thereof, pyrazinamide or a pharmaceutically acceptable salt thereof and ethambutol or a pharmaceutically acceptable salt thereof, wherein rifampin and isoniazid are in separate layers. The invention also provides a pharmaceutical composition prepared therefrom having advantageous stability and bioavailability.||02-02-2012|
|20110276161||Server for Integrated Pharmaceutical Analysis and Report Generation Service, Method of Integrated Pharmaceutical Manufacturing and Research and Development Numerical Analysis, and Computer Readable Recording Medium - A web-based tool (as a server) for integrated pharmaceutical analysis and report generation service is provided in the present invention. The server can be used for numerical analysis and report generation for pharmaceutical manufacturing, research and development, and has advantages such as simple operation, complicated but fast calculation and professional report generation, and high accuracy. The server includes at least one pharmaceutical manufacturing and research and development numerical analysis system configured to perform different pharmaceutical manufacturing and research and development numerical analyses and generate different reports. Each of the at least one pharmaceutical manufacturing and research and development numerical analysis system includes an input module configured to receive, via a user interface, at least one of a template file and a backup file previously output by the server as at least one input file, wherein the at least one input file includes a plurality of data fields to provide corresponding data; at least one calculation module, each configured to execute a built-in pharmaceutical manufacturing and research and development numerical analysis calculation program, thereby automatically performing a pharmaceutical manufacturing and research and development numerical analysis calculation on at least one of the data of the at least one input file and on-line filled data; and an output module configured to generate at least one of a backup file and a report file as at least one output file based on the result of the pharmaceutical manufacturing and research and development numerical analysis calculation performed by the at least one calculation module and provide the at least one file via the user interface.||11-10-2011|
|20110101553||METHOD AND DEVICE FOR CONTINUOUSLY PREPARING MICROSPHERES, AND COLLECTION UNIT THEREOF - A method and a device for continuously preparing microspheres, and a collection unit thereof are provided. The collection unit for collecting microspheres in the solution comprises a tank and a first plate. The first plate is removably disposed in the tank. The first plate, when lay across the tank, has its two ends came in contact with the sidewall of the tank so as to divide the tank into a first chamber and a second chamber. The tank has an outlet located in the second chamber. After the solution with microspheres are input to the first chamber of the tank, the microspheres are deposited around the first plate, and the solution is caused to pass through or over the first plate to the second chamber and output from the outlet.||05-05-2011|
|20100081669||PRESSURE SENSITIVE ADHESIVE MATRIX DEVICE OR SYSTEM FOR THE TREATMENT OR PREVENTION OF ONYCHOMYCOSIS OR TINEA PEDIS - Disclosed is a pressure-sensitive adhesive matrix patch device for treatment or prevention of fungal toenails or fingernails or foot infections comprising an antifungal agent or two or more antifungals in combination and adhesively secured to a dorsal site of an infected palm or foot, rather than an area of infection and surrounding skin. A method for the transdermal treatment or prevention of fungal toenails or fingernails or foot infections with an antifungal agent is also disclosed, the method comprising adhesively securing to a dorsal site of an infected palm or foot a pressure-sensitive adhesive matrix patch device for a time sufficient to deliver an effective amount of the antifungal agent to an area of infection.||04-01-2010|
|20090186087||ENTERIC SUSTAINED-RELEASE COATED CORE AND PHARMACEUTICAL DOSAGE FORM AND METHOD FOR MANUFACTURING THE SAME - An enteric sustained-release coated core includes a drug-containing core and a coating film. The coating film includes 20%˜80% by weight of a hydrophobic polymer and 10%˜70% by weight of an enterosoluble material. The dissolution rate of the medical component in the drug-containing core is approximately less than 10% in hydrochloric acid solution of pH 1˜3 after 2 hours. The dissolution of the medical component in the drug-containing core sustains more than 5 hours in phosphate buffer solution of pH 5˜8.||07-23-2009|
Patent applications by TAIWAN BIOTECH CO., LTD.